Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

5 march 2024

07:30
UroToday, the premier global hub for urology news and education, and PRIMR, a pioneering oncology clinical trial patient education company, proudly announce their inaugural strategic partnership. This groundbreaking collaboration is set to redefine...

07:05
REGENXBIO Inc.  today reported additional interim safety...

07:00
The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by ASPR/BARDA and NIH/NIAID, in collaboration with Battelle[1], have selected opaganib for evaluation...

07:00
A new, preclinical study highlights the abilities of a beauty-from-within botanical-blend Zeropollution® to shield skin from the adverse effects of city pollution, especially from free radical damage on a cellular level....

07:00
ClinOne, a trailblazing provider of clinical trial technology, announces today a significant enhancement to its platform that empowers customers like never before. In addition to its full-service technology offerings, ClinOne now enables even more...

07:00
CASI Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") , a biotech company focused on the...

07:00
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie  to evaluate ABBV-303,...

07:00
Oncolytics Biotech® Inc. , a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in...

07:00
Sonata Therapeutics, a biotechnology company developing a new class of therapeutics called Network Medicinestm, and the Champalimaud Foundation, a world leader in biomedical research and academic medicine, today announced a research collaboration for...

06:32
IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office in Boston, Massachusetts, a cornerstone for biotechnology and drug discovery. This strategic initiative underscores IRBM's...

04:00
Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today that it has received Fast Track designation from the U.S. Food...


4 march 2024

21:05
Cynata Therapeutics Limited , a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host...

13:53
Amprion is pleased to announce its presence at the AD/PDtm 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal on March 5-9. Amprion's ?Syn seed amplification...

13:18
BRAINBox Solutions today announced current and upcoming presentations of clinical trends and data at three leading, upcoming medical conferences from the HeadSMART II pivotal trial in adult patients and the National Institutes of Health (NIH) funded...

13:17
In the news release, QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia, issued 04-Mar-2024 by QurAlis over PR Newswire, we are advised by the company that the dates for the...

13:03
Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company's phase 2 clinical...

09:00
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two posters in Parkinson's disease (PD) will be shared at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024), being held in Lisbon, Portugal, and virtually,...

09:00
WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the introduction of Statistical Consulting Solutions. Developed to combat some of the pervasive...

08:30
IceCure Medical Ltd. ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that results from an...

08:30
Valo Health, Inc (Valo), a technology company focused on utilizing large scale data and artificial intelligence (AI) driven computation to discover and develop therapeutics, today announced full enrollment in the company's Phase 2 Spectra clinical...

08:30
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar DepressionThe study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafterStudy maintained 95%...

08:08
Neurocode USA, Inc, a specialized clinical laboratory that offers world-class testing solutions for neurological disorders, is pleased to announce the clinical launch of ALZpath Dx, an innovative and novel blood test that can be used in the...

08:02
Berlin Cures, a clinical-stage...

08:00
Fauna Bio, biotechnology company improving human health by leveraging animal genomics, announced today Dr. Lara Do Amaral-Silva, assistant professor of biology at Wake Forest University, as the recipient of the FaunaBio Translational Research Award...

07:45
QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter the trajectory of amyotrophic...

07:00
Avidity accelerates global Phase 3 HARBORtm study initiation to Q2 2024 following regulatory agreement on study design; primary endpoint is video hand opening time (vHOT) and secondary endpoints include muscle strength and activities of daily living...

07:00
YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially  approved the...

06:50
BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which will assess the safety and effectiveness of...

04:55
MGI Tech, a company committed to building core tools and technology to lead life science, today proudly announced a milestone collaboration with Eurofins Genomics Europe Genotyping A/S ("Eurofins Genomics"), which has placed a corporate order of the...

03:36
The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and...


3 march 2024

18:31
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHTtm 2 Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for...

18:00
Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CBL-514 for Dercum's disease treatment. CBL-514 is a lipolysis injection that can reduce local subcutaneous fat...


1 march 2024

17:21
Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial. The company is pleased to announce Dr....

16:08
Aadi Bioscience, Inc. , a biopharmaceutical company focused on developing and...

15:59
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with...

09:00
NeuroKey-3tm measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer's Disease and Dementia pathology, including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and...

09:00
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla.,...

08:50
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today the National Medical Products Administration...

08:35
Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously announced pursuit of strategic...

06:55
Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENTtm Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery...

01:55
Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of the U.S....


29 february 2024

19:00
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major...

17:54
Pedaling on a stationary bicycle built for two may improve the health and well-being for both people with Parkinson's disease and their care partners, according to a small, preliminary study released February 29, 2024, that will be presented at the...

16:57
REGENXBIO Inc. today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202...

13:35
As reported in today's issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular...

13:00
Spatz Medical, a global leader in gastrointestinal weight loss solutions, is delighted to announce the commencement of commercialization of the Spatz3 Adjustable Gastric Balloon. With over 150,000 patients benefiting from the Spatz3 across more than...

10:49
US patients are willing to share their health data across clinical trials studies, offering the potential for global biopharma organizations to radically increase the pace of R&D, according to new data from PA Consulting (PA), the company that's...

09:00
Today, researchers at Vivacelle Bio, Inc., a pioneering biotechnology company revealed the compelling outcomes of their phase 2a clinical trial of the investigational cardiovascular support fluid, VBI-S, in patients with severe septic shock. This...

09:00
Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of Pharmasite Research, an established clinical trial site dedicated to research in mental illness and disorders of the central nervous...

09:00
LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies, announces the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16